Clinical Trial

A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy, LBL-024 in combination with LBL-007 or toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-25; most recent amendment 2026-05-15.
Status change: Not Yet Recruiting → Recruiting 2025-09-12
Trial Details
NCT Number NCT07099430
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Conditions Advanced Melanoma
Enrollment 200 participants
Start Date 2025-09-05
Primary Completion 2027-10-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-18